Article
Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 1 Dec 2016
Laguno M, Von Wichmann M A, Van den Eynde E, Navarro J, Cifuentes C, Murillas J, Veloso S, Martínez-Rebollar M, Guardiola J M, Jou A, Gómez-Sirvent J L, Cervantes M, Pineda J A, López-Calvo S, Carrero A, Montes M L, Deig E, Tapiz A, Ruiz-Mesa J D, Cruceta A, de Lazzari E, Mallolas J
Abstract excerpt
INTRODUCTION: Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC+pegylated interferon-α2a/ribavirin (PEG-IFN/RBV) in the retreatment of HIV-HCV co-infected patients with HCV genotype 1. METHODS: This was a phase III prospective trial. HIV-HCV (genotype 1) co-infected patients from 16 hospitals in Spain...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.